1. FRI0211 A descriptive analysis of real-world treatment patterns of innovator infliximab (REMICADE) and biosimilar infliximab in a treatment naÏve turkish rheumatologic disease population. (15th June 2017) Authors: Yazici, Y; Xie, L; Ogbomo, A; Parenti, D; Goyal, K; Teeple, A; Ellis, L; Simsek, I Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0175 A descriptive analysis of real-world treatment patterns in a turkish rheumatology population that continued innovator infliximab (REMICADE) therapy or switched to biosimilar infliximab. (15th June 2017) Authors: Yazici, Y; Xie, L; Ogbomo, A; Parenti, D; Goyal, K; Teeple, A; Ellis, L; Simsek, I Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 836 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0465 An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriatic arthritis, crohn's disease, and psoriasis. (15th June 2017) Authors: Gensler, LS; Hsia, E; Gasink, C; Randazzo, B; Parenti, D; Fakharzadeh, S; Gao, L-L; Chakravarty, SD Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 950 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0672 Real world evidence comparing the patient reported outcomes measurement information system to the cdai in rheumatoid arthritis patients. (15th June 2017) Authors: Curtis, JR; Kafka, S; Parenti, D; Black, S; Xu, S; Wang, Y; Bingham, CO Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗